H.C. Wainwright reiterates Crescent Biopharma stock rating at buy
H.C. Wainwright reiterated a Buy rating and $36.00 price target on Crescent Biopharma (CBIO), citing progress in mid-stage clinical trials for its CR-001 drug. The stock trades at $11.84, with potential upside of over 200%. Crescent announced completion of dose escalation in its ASCEND trial and enrollment of over 125 patients. The company aims to dose over 2,000 patients by mid-2027 and start Phase 3 trials in early 2028.
How this was made
The 30-second read
Why it matters
The reiterated Buy rating and higher target could attract short‑term buying, but the long‑term upside depends on upcoming efficacy readouts in 2027.
Market read
Analyst upgrade provides a fresh catalyst for CBIO, potentially moving the stock ahead of its upcoming trial readouts.
What to watch
Competition from Merck's MK‑2010 program could limit partnership opportunities for Crescent.
Background
Crescent Biopharma is advancing its CR‑001 ADC candidate through dose escalation and combination cohorts, while analysts raise price targets.
Ticker impact
H.C. Wainwright reiterated a Buy rating and set a $36 price target, citing progress in mid‑stage trials for CR‑001 and upcoming data catalysts.
likely upward pressure as investors price in the upgrade and trial milestones
The upgrade is a fresh catalyst; the stock is currently at $11.84, implying >200% upside to the target.
Market effects
Biotech sector may see renewed interest in ADC platforms as trial data progresses.
U.S. biotech investors could allocate more capital to early‑stage clinical developers.
Potentially modest impact on global biotech sentiment, limited to firms with similar pipelines.
Counterpoint
The trial data is still early; investors may wait for Phase 3 readouts before committing.
Key entities
- companyCrescent Biopharma Inc
NASDAQ‑listed biotech developing antibody‑drug conjugates.
- analyst_firmH.C. Wainwright
Equity research firm that issued the Buy rating.
